While the first CN patent linkage declaration was reported in my
post below, that was a non-contentious type 3 declaration, i.e. the
generic drug applicant undertakes that they would only put their
drug onto the market after the patents have expired.
https://www.linkedin.com/posts/tobymak_first-in-china-patent-linkage-notification-activity-6820520545168293888-sVr5
Thanks for heads-up from Indira TK, on 23 July 2021, the first
contentious CN patent linkage declaration was announced,
directed to the drug dapagliflozin
(达格列净) 5 and 10 mg, with AstraZeneca as
the drug marketing approval owner in China. The relevant screen
shot for the 5mg drug is shown above, while that of the 10 mg drug
has similar contents.
